LDC1267 是一种特异性 TAM(Tyro3, Axl and Mer) 激酶抑制剂，能够作用于 Mer( IC50<5 nM)、Tyro3(IC50:8 nM) 和 Axl(IC50:29 nM)。

LDC1267 is a excellently specific TAM(Tyro3, Axl and Mer) kinase inhibitor, for Mer( IC50<5 nM), Tyro3(IC50=8 nM), and Axl(IC50=29 nM).

在负荷B16F10黑素瘤的小鼠体内, 腹腔内注射LDC1267（20 mg/kg）具有较高的安全性,能够抑制肿瘤代谢,增强具有抗转移NK细胞的活性.

在多种的细胞系中,LDC1267对于细胞产生抑制增殖的作用,IC50 >5 μM。在NKG2D激活的NK细胞中,LDC1267能够阻断由Gas6刺激引起的抑制作用。

Kinase binding assays: For optimization of Axl/TAM receptor inhibitors, an Axl binding assay is established (HTRF method; Kinase tracer 236). This assay is based on the binding and displacement of the Alexa Fluor 647-labelled Kinase tracer 236 to each glutathione S-transferase (GST)-tagged kinase used in the binding assay. Binding of the tracer to the kinase was detected by using europium (Eu)-labelled anti-GST antibodies. Simultaneous binding of both the fluorescent tracer and the Eu-labelled antibodies to the GST-tagged kinase generates a fluorescence resonance energy transfer (FRET) signal. Binding of inhibitor to the kinase competes for binding with the tracer, resulting in a loss of the FRET signal. For the assay, the compound is diluted in 20?mM HEPES, pH?8.0, 1?mM DTT, 10?mM MgCl2 and 0.01% Brij35. Then, the kinase of interest (5?nM final concentration), fluorescent tracer (15?nM final concentration) and LanthaScreen Eu-anti-GST antibody (2?nM final concentration) are mixed with the respective compound dilutions (from 5?nM to 10?μM) and incubated for 1?h. The FRET signal is quantified using an EnVision Multilabellreader 2104.

After incubation for 72?hours with LDC1267, CellTiterGlow reagent is used to determine the proliferation relative to the corresponding DMSO control.(Only for Reference)

1361030-48-9

C30H26F2N4O5

560.55

Ethanol:2 mg/mL (3.56 mM),warmed
DMSO:93 mg/mL (165.9 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years